How could LabCorp's expanded diagnostic capacity affect Applied DNA Sciences?
LabCorp's expanded diagnostic capacity may increase competitive pressure on Applied DNA Sciences The sale of Myriad Genetics' Prenatal Health testing business to LabCorp significantly boosts LabCorp's specialized diagnostic offerings. Labcorp acquired tests including Prequel®, Foresight®, SneakPeek®, and FirstGene®, which were previously used by over 600,000 patients. This expansion is expected to add approximately $160 million in revenue to Labcorp in year one. As Applied DNA Sciences is identified as a competitor to Myriad Genetics, this increased scale and specialized capacity from Labcorp could intensify market competition for both companies.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Gone quiet
How it reaches Applied DNA Sciences
-
Myriad Genetics announced it is selling its Prenatal Health testing business to LabCorp. The transaction includes tests such as Prequel®, Foresight®, SneakPeek®, and FirstGene®. LabCorp will acquire the business for $210 million in cash, plus the value of the inventory.
The full event1independent outlet -
The acquisition is expected to add approximately $160 million in revenue to Labcorp in year one, strengthening its position in the diagnostics market. Since Applied DNA Sciences is identified as a competitor to Myriad Genetics, Labcorp's increased scale and specialized offerings could intensify market competition for Applied DNA Sciences.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American high-technology company
Everything about Applied DNA Sciences
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Myriad Genetics divested its Prenatal Health testing business to LabCorp for $210 million in cash, plus inventory value.manilatimes.net
- The Prenatal Health testing business includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests.manilatimes.net
- Over the last twelve months, Myriad’s Prenatal Health testing portfolio was used by thousands of providers and over 600,000 patients.manilatimes.net
- Labcorp expects the transaction to add approximately $160 million in revenue in year one.manilatimes.net
Why it matters
Applied DNA Sciences operates in the high-technology healthcare sector, and its competitive standing is directly tied to the market dominance of major players like Myriad Genetics and LabCorp. The acquisition by Labcorp represents a significant consolidation of specialized reproductive genetics capabilities, allowing Labcorp to expand its market reach and revenue base substantially.
This move strengthens Labcorp's position as a global leader in comprehensive laboratory services. For Applied DNA Sciences, which is identified as a competitor to Myriad Genetics, the increased scale and specialized portfolio of Labcorp could force changes in strategy, pricing, or investment to maintain market share.
What we don't know yet
- How will Applied DNA Sciences respond to the increased competitive pressure from LabCorp?
- Will the acquisition lead to immediate changes in the pricing of prenatal testing services?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Quest DiagnosticsPossibleQuest Diagnostics may face increased competition from LabCorp's expanded prenatal testing portfolio.
- FDAPossibleLabcorp's expanded prenatal testing portfolio may require FDA review
- MedicarePossibleIncreased prenatal testing volume could expand Medicare's utilization of lab services.
Reporting
- manilatimes.netOct 20
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.